EUVIMEDEUVIMED entdecken
Crossref

Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy

J R Wunderlich, D Mezzanzanica, M A Garrido, D S Neblock, P E Daddona, S M Andrew, V R Zurawski, S Canevari, M I Colnaghi, D M Segal

International Journal of Clinical and Laboratory Research · 1992

DOI: 10.1007/bf02591388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical and Laboratory Research, 1992. Verfasst von J R Wunderlich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have used a relatively new technology to increase the number of human lymphocytes that will react with human ovarian carcinoma cells. This technology, often called "retargeting of the immune system," can temporarily redirect the activity of immune cells that were originally committed to react with foreign substances other than cancer cells. In the example presented here, the antitumor effects of retargeted human T lymphocytes, collected from normal donors, were tested in immunodeficient mice with a human ovarian carcinoma line growing intraperitoneally. We retargeted T cells in vitro with a bispecific antibody that reacted with the T cell receptor complex and with a cell-surface antigen expressed by the ovarian carcinoma cells. Retargeted lymphocytes, injected intraperitoneally into mice 4 days after intraperitoneal injection of the tumor cells, impeded tumor growth and doubled the host survival time. These findings provide support for the concept that treatment of ovarian cancer patients with retargeted T cells could prove beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAntibodiesAntibodies, MonoclonalAntibody SpecificityCytotoxicity, ImmunologicFemaleLymphocyte ActivationMiceMice, NudeOvarian NeoplasmsSurvival RateT-LymphocytesTumor Cells, Cultured

Substanzen

AntibodiesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892.

Zitieren

APA

Wunderlich, J. R., Mezzanzanica, D., Garrido, M. A., Neblock, D. S., Daddona, P. E., Andrew, S. M., Zurawski, V. R., Canevari, S., Colnaghi, M. I., & Segal, D. M. (1992). Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. International Journal of Clinical and Laboratory Research. https://doi.org/10.1007/bf02591388

Vancouver

Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, et al. Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. International Journal of Clinical and Laboratory Research. 1992. doi:10.1007/bf02591388

BibTeX
@article{Wunderlich1992,
  author = {Wunderlich, J R and Mezzanzanica, D and Garrido, M A and Neblock, D S and Daddona, P E and Andrew, S M and Zurawski, V R and Canevari, S and Colnaghi, M I and Segal, D M},
  title = {Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy},
  journal = {International Journal of Clinical and Laboratory Research},
  year = {1992},
  doi = {10.1007/bf02591388}
}
Kostenlos starten →